Penumbra Initiates FORWARD Study to Enhance Ischemic Stroke Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: PRnewswire
- Study Launch: Penumbra, Inc. has announced the initiation of the FORWARD study, aimed at collecting safety and efficacy data on mechanical thrombectomy for acute ischemic stroke, with plans to enroll up to 250 participants across approximately 40 centers, marking a significant advancement in this field.
- Technological Innovation: The study will evaluate Penumbra's market-leading RED reperfusion catheter portfolio, including the first CAVT platform, THUNDERBOLT, designed to improve treatment outcomes for patients with M2 occlusions through modulated aspiration, potentially offering new treatment options for this patient population.
- Clinical Significance: The results of the FORWARD study will assist physicians in better selecting treatment options for M2 occlusions, potentially supporting wider adoption of mechanical thrombectomy for this challenging condition, thereby improving patient outcomes and quality of life.
- Market Potential: Ischemic stroke remains the third leading cause of death and disability globally, with approximately 11.9 million new cases in 2021 and an estimated 21,000 to 66,000 M2 strokes occurring annually, and the success of the FORWARD study could further solidify Penumbra's leadership position in this critical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 318.310
Low
266.00
Averages
344.64
High
388.00
Current: 318.310
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Penumbra Initiates FORWARD Study to Enhance Ischemic Stroke Treatment
- Study Launch: Penumbra, Inc. has announced the initiation of the FORWARD study, aimed at collecting safety and efficacy data on mechanical thrombectomy for acute ischemic stroke, with plans to enroll up to 250 participants across approximately 40 centers, marking a significant advancement in this field.
- Technological Innovation: The study will evaluate Penumbra's market-leading RED reperfusion catheter portfolio, including the first CAVT platform, THUNDERBOLT, designed to improve treatment outcomes for patients with M2 occlusions through modulated aspiration, potentially offering new treatment options for this patient population.
- Clinical Significance: The results of the FORWARD study will assist physicians in better selecting treatment options for M2 occlusions, potentially supporting wider adoption of mechanical thrombectomy for this challenging condition, thereby improving patient outcomes and quality of life.
- Market Potential: Ischemic stroke remains the third leading cause of death and disability globally, with approximately 11.9 million new cases in 2021 and an estimated 21,000 to 66,000 M2 strokes occurring annually, and the success of the FORWARD study could further solidify Penumbra's leadership position in this critical market.
See More
THUNDERBOLT Technology Secures CE Mark for Stroke Treatment
- Technological Innovation: Penumbra's THUNDERBOLT™ technology has received CE Mark approval, introducing modulated aspiration for the first time in acute ischemic stroke treatment, significantly enhancing the speed and completeness of clot removal, thereby improving patient outcomes and safety.
- Market Leadership: As the only computer-assisted vacuum thrombectomy (CAVT™) device available in Europe and the U.S., the launch of THUNDERBOLT represents a significant advancement in acute ischemic stroke care, expected to bolster Penumbra's leadership position in the global market.
- Clinical Impact: Research indicates that global stroke mortality is projected to increase by 50% from 2020 to 2050, and the application of THUNDERBOLT is anticipated to address this challenge by shortening procedure times and improving patient outcomes, enhancing the efficiency of healthcare services.
- Strategic Positioning: The introduction of THUNDERBOLT technology in Europe reflects Penumbra's commitment to equipping physicians with the most advanced stroke care tools, further solidifying its market position in the neurovascular field.
See More
Penumbra Launches THUNDERBOLT Platform for Stroke Treatment
- FDA Approval: Penumbra has received FDA clearance for THUNDERBOLT™, the first computer-assisted vacuum thrombectomy (CAVT) platform for acute ischemic stroke, marking a significant advancement in stroke treatment that is expected to greatly improve patient recovery chances.
- Innovative Design Benefits: THUNDERBOLT features modulated aspiration technology that allows for rapid and safe clot capture while minimizing catheter manipulation, quickly restoring blood flow to the brain and providing patients with the best chance for recovery, which is critical in stroke treatment.
- Market Uniqueness: As the only CAVT device available in the U.S., the launch of THUNDERBOLT not only fills a market gap but also reinforces Penumbra's leadership position in thrombectomy, which is anticipated to drive future growth for the company.
- Global Stroke Challenge: With global stroke mortality projected to increase by 50% from 2020 to 2050 and someone suffering a stroke every 40 seconds in the U.S., the introduction of THUNDERBOLT offers a new solution to address this escalating public health issue.
See More
Penumbra's THUNDERBOLT Technology Receives FDA Clearance for Stroke Treatment
- Innovative Approval: Penumbra's THUNDERBOLT™ has received FDA clearance, becoming the first computer-assisted vacuum thrombectomy (CAVT) platform for acute ischemic stroke, marking a significant advancement in stroke treatment.
- Clinical Impact: THUNDERBOLT minimizes catheter manipulation, promoting safe and complete clot capture, which quickly restores blood flow to the brain, thereby providing patients with the best chance for recovery and is expected to significantly improve outcomes for patients with emergent large vessel occlusion.
- Market Uniqueness: As the only CAVT device available for stroke treatment in the U.S., THUNDERBOLT not only fills a market gap but also has the potential to set new treatment standards in future stroke management, enhancing Penumbra's competitiveness in the medical device industry.
- Clear Strategic Positioning: Penumbra is committed to redefining stroke care, and the launch of THUNDERBOLT aligns with the company's long-standing innovation promise in clot treatment, which is expected to drive market expansion and business growth globally.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Overview: Halper Sadeh LLC is investigating companies like TopBuild Corp., Penumbra, Inc., and European Wax Center, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights and transaction terms.
- TopBuild Transaction Details: TopBuild shareholders can elect to receive $505.00 in cash or 20.2 shares of QXO common stock per share, with terms that may limit superior competing offers, potentially affecting shareholder returns.
- Penumbra Shareholder Options: Penumbra shareholders can choose between $374.00 in cash or 3.8721 shares of Boston Scientific common stock, and Halper Sadeh LLC may seek increased consideration or other remedies to protect shareholder interests.
- European Wax Cash Acquisition: European Wax shareholders will sell their shares for $5.80 in cash each, and Halper Sadeh LLC encourages shareholders to understand their rights and options to ensure they receive appropriate compensation and disclosures.
See More
Penumbra Reports 90-Day Results of STORM-PE Trial
- Clinical Trial Results: Penumbra's STORM-PE trial revealed that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy (CAVT™) plus anticoagulation showed significant functional improvements at 90 days, including increased walking distance and a higher proportion achieving NYHA Class I, indicating the substantial clinical potential of CAVT.
- Safety Confirmation: Over the 90-day observation period, safety rates were comparable between the CAVT and anticoagulation groups, with no device-related mortality and no significant differences in PE-related mortality after 7 days, further validating the safety profile of CAVT and supporting its clinical application.
- Evolving Treatment Strategies: The results from the STORM-PE trial underscore the importance of CAVT in treating intermediate-high risk pulmonary embolism, potentially leading to a shift in future clinical guidelines towards broader adoption of endovascular treatment options, thereby improving patient recovery and quality of life.
- Future Research Directions: The upcoming STRIKE-PE study, set to present on April 15, will provide long-term quality-of-life and functional outcome data for CAVT in male and female pulmonary embolism patients, further validating the clinical efficacy of CAVT and advancing the treatment landscape for pulmonary embolism.
See More
Penumbra Initiates FORWARD Study to Enhance Ischemic Stroke Treatment
- Study Launch: Penumbra, Inc. has announced the initiation of the FORWARD study, aimed at collecting safety and efficacy data on mechanical thrombectomy for acute ischemic stroke, with plans to enroll up to 250 participants across approximately 40 centers, marking a significant advancement in this field.
- Technological Innovation: The study will evaluate Penumbra's market-leading RED reperfusion catheter portfolio, including the first CAVT platform, THUNDERBOLT, designed to improve treatment outcomes for patients with M2 occlusions through modulated aspiration, potentially offering new treatment options for this patient population.
- Clinical Significance: The results of the FORWARD study will assist physicians in better selecting treatment options for M2 occlusions, potentially supporting wider adoption of mechanical thrombectomy for this challenging condition, thereby improving patient outcomes and quality of life.
- Market Potential: Ischemic stroke remains the third leading cause of death and disability globally, with approximately 11.9 million new cases in 2021 and an estimated 21,000 to 66,000 M2 strokes occurring annually, and the success of the FORWARD study could further solidify Penumbra's leadership position in this critical market.
See More
THUNDERBOLT Technology Secures CE Mark for Stroke Treatment
- Technological Innovation: Penumbra's THUNDERBOLT™ technology has received CE Mark approval, introducing modulated aspiration for the first time in acute ischemic stroke treatment, significantly enhancing the speed and completeness of clot removal, thereby improving patient outcomes and safety.
- Market Leadership: As the only computer-assisted vacuum thrombectomy (CAVT™) device available in Europe and the U.S., the launch of THUNDERBOLT represents a significant advancement in acute ischemic stroke care, expected to bolster Penumbra's leadership position in the global market.
- Clinical Impact: Research indicates that global stroke mortality is projected to increase by 50% from 2020 to 2050, and the application of THUNDERBOLT is anticipated to address this challenge by shortening procedure times and improving patient outcomes, enhancing the efficiency of healthcare services.
- Strategic Positioning: The introduction of THUNDERBOLT technology in Europe reflects Penumbra's commitment to equipping physicians with the most advanced stroke care tools, further solidifying its market position in the neurovascular field.
See More
Penumbra Launches THUNDERBOLT Platform for Stroke Treatment
- FDA Approval: Penumbra has received FDA clearance for THUNDERBOLT™, the first computer-assisted vacuum thrombectomy (CAVT) platform for acute ischemic stroke, marking a significant advancement in stroke treatment that is expected to greatly improve patient recovery chances.
- Innovative Design Benefits: THUNDERBOLT features modulated aspiration technology that allows for rapid and safe clot capture while minimizing catheter manipulation, quickly restoring blood flow to the brain and providing patients with the best chance for recovery, which is critical in stroke treatment.
- Market Uniqueness: As the only CAVT device available in the U.S., the launch of THUNDERBOLT not only fills a market gap but also reinforces Penumbra's leadership position in thrombectomy, which is anticipated to drive future growth for the company.
- Global Stroke Challenge: With global stroke mortality projected to increase by 50% from 2020 to 2050 and someone suffering a stroke every 40 seconds in the U.S., the introduction of THUNDERBOLT offers a new solution to address this escalating public health issue.
See More
Penumbra's THUNDERBOLT Technology Receives FDA Clearance for Stroke Treatment
- Innovative Approval: Penumbra's THUNDERBOLT™ has received FDA clearance, becoming the first computer-assisted vacuum thrombectomy (CAVT) platform for acute ischemic stroke, marking a significant advancement in stroke treatment.
- Clinical Impact: THUNDERBOLT minimizes catheter manipulation, promoting safe and complete clot capture, which quickly restores blood flow to the brain, thereby providing patients with the best chance for recovery and is expected to significantly improve outcomes for patients with emergent large vessel occlusion.
- Market Uniqueness: As the only CAVT device available for stroke treatment in the U.S., THUNDERBOLT not only fills a market gap but also has the potential to set new treatment standards in future stroke management, enhancing Penumbra's competitiveness in the medical device industry.
- Clear Strategic Positioning: Penumbra is committed to redefining stroke care, and the launch of THUNDERBOLT aligns with the company's long-standing innovation promise in clot treatment, which is expected to drive market expansion and business growth globally.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Overview: Halper Sadeh LLC is investigating companies like TopBuild Corp., Penumbra, Inc., and European Wax Center, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights and transaction terms.
- TopBuild Transaction Details: TopBuild shareholders can elect to receive $505.00 in cash or 20.2 shares of QXO common stock per share, with terms that may limit superior competing offers, potentially affecting shareholder returns.
- Penumbra Shareholder Options: Penumbra shareholders can choose between $374.00 in cash or 3.8721 shares of Boston Scientific common stock, and Halper Sadeh LLC may seek increased consideration or other remedies to protect shareholder interests.
- European Wax Cash Acquisition: European Wax shareholders will sell their shares for $5.80 in cash each, and Halper Sadeh LLC encourages shareholders to understand their rights and options to ensure they receive appropriate compensation and disclosures.
See More
Penumbra Reports 90-Day Results of STORM-PE Trial
- Clinical Trial Results: Penumbra's STORM-PE trial revealed that patients with acute intermediate-high risk pulmonary embolism treated with computer-assisted vacuum thrombectomy (CAVT™) plus anticoagulation showed significant functional improvements at 90 days, including increased walking distance and a higher proportion achieving NYHA Class I, indicating the substantial clinical potential of CAVT.
- Safety Confirmation: Over the 90-day observation period, safety rates were comparable between the CAVT and anticoagulation groups, with no device-related mortality and no significant differences in PE-related mortality after 7 days, further validating the safety profile of CAVT and supporting its clinical application.
- Evolving Treatment Strategies: The results from the STORM-PE trial underscore the importance of CAVT in treating intermediate-high risk pulmonary embolism, potentially leading to a shift in future clinical guidelines towards broader adoption of endovascular treatment options, thereby improving patient recovery and quality of life.
- Future Research Directions: The upcoming STRIKE-PE study, set to present on April 15, will provide long-term quality-of-life and functional outcome data for CAVT in male and female pulmonary embolism patients, further validating the clinical efficacy of CAVT and advancing the treatment landscape for pulmonary embolism.
See More
